Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.28B 11.31B 10.5B 19.94B 1,337B 20.21B 135B 52.69B 657B 52.66B 51.5B 2,276B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.42B 10.52B 9.76B 18.54B 1,244B 18.79B 126B 48.99B 610B 48.96B 47.89B 2,116B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Compliance Officer 64 2019-07-01
Chief Tech/Sci/R&D Officer - 2022-03-31
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
25-04-01Issuer sale

Executive Vice President & CFO

75,024 0.0706%
25-04-01Issuer sale

Director

242,551 0.2281%
25-04-01Issuer sale

Chief Executive Officer

2,048,863 1.9269%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+105.73% 14.02B
-0.68%+2.85%+18.72%-7.81% 66.11B
-1.97%-3.45%+50.62%+221.13% 55.3B
-1.13%+40.50%+40.50%+40.50% 42.44B
-0.21%+8.04%-50.01%-53.55% 41.28B
-3.54%-3.77%+56.89%-26.85% 30.78B
+2.56%+17.36%+168.28%-30.85% 32.46B
-1.06%+0.84%+68.91%+83.93% 23.1B
-4.09%+9.05%+5.15%+186.94% 20.06B
+0.21%+3.76%+66.67%+133.69% 17.19B
Average -0.99%+4.72%+42.57%+65.29% 34.27B
Weighted average by Cap. -0.99%+3.88%+40.10%+55.03%

Financials

2023 2024
Net sales 464M 407M 375M 348M 660M 44.3B 669M 4.48B 1.75B 21.74B 1.74B 1.71B 75.39B 681M 596M 549M 510M 968M 64.94B 981M 6.57B 2.56B 31.88B 2.56B 2.5B 111B
Net income -140M -122M -113M -105M -199M -13.32B -201M -1.35B -525M -6.54B -525M -513M -22.67B -74.68M -65.4M -60.24M -55.91M -106M -7.12B -108M -721M -281M -3.5B -280M -274M -12.12B
Net Debt -481M -421M -388M -360M -684M -45.88B -693M -4.64B -1.81B -22.52B -1.81B -1.77B -78.09B -984M -862M -794M -737M -1.4B -93.87B -1.42B -9.5B -3.7B -46.08B -3.7B -3.61B -160B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock